Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combinati...
Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotecti...
Preclinical studies have highlighted how (E,E)-bisantrene silences c-MYC gene expression via G4-DNA...